$487 Million is the total value of GREAT POINT PARTNERS LLC's 35 reported holdings in Q4 2016. The portfolio turnover from Q3 2016 to Q4 2016 was 61.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| VNDA | Sell | VANDA PHARMACEUTICALS INC | $32,060,000 | -28.8% | 2,010,000 | -25.7% | 6.59% | -42.7% |
| SGYPQ | Sell | SYNERGY PHARMACEUTICALS DEL | $30,289,000 | -14.4% | 4,973,509 | -22.6% | 6.22% | -31.0% |
| DERM | Sell | DERMIRA INC | $3,460,000 | -84.9% | 114,080 | -83.2% | 0.71% | -87.9% |
| ALIM | Sell | ALIMERA SCIENCES INC | $2,477,000 | -37.0% | 2,293,675 | -13.1% | 0.51% | -49.3% |
| ARDMQ | Sell | ARADIGM CORP | $1,267,000 | -81.6% | 791,870 | -21.0% | 0.26% | -85.2% |
| ARDX | Exit | ARDELYX INC CMN | $0 | – | -15,000 | -100.0% | -0.05% | – |
| NVAX | Exit | CALL/NVAX @ 8 EXP 10/21/2016call | $0 | – | -409,200 | -100.0% | -0.22% | – |
| MCRB | Exit | PUT/MCRB @ 20 EXP 10/21/2016put | $0 | – | -120,000 | -100.0% | -0.38% | – |
| MCRB | Exit | SERES THERAPEUTICS, INC. CMN | $0 | – | -120,000 | -100.0% | -0.38% | – |
| TTPH | Exit | TETRAPHASE PHARMACEUTICALS INC CMN | $0 | – | -452,375 | -100.0% | -0.44% | – |
| PDLI | Exit | PDL BIOPHARMA INC CMN | $0 | – | -645,000 | -100.0% | -0.55% | – |
| DPRX | Exit | DIPEXIUM PHARMACEUTICALS INC CMN | $0 | – | -178,930 | -100.0% | -0.66% | – |
| GWPH | Exit | PUT/GWPH @ 95 EXP 10/21/2016put | $0 | – | -23,800 | -100.0% | -0.81% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STREAMLINE HEALTH SOLUTNS, INC CMN | 25 | Q3 2019 | 2.5% |
| IOVANCE BIOTHERAPEUTICS, INC. CMN | 16 | Q1 2021 | 14.3% |
| ZOGENIX INC CMN | 16 | Q4 2019 | 8.8% |
| PTC THERAPEUTICS, INC. CMN | 16 | Q3 2023 | 9.9% |
| EXELIXIS, INC | 16 | Q1 2022 | 7.5% |
| SAGE THERAPEUTICS, INC CMN | 15 | Q3 2021 | 10.8% |
| CYTOKINETICS INC | 15 | Q3 2023 | 5.8% |
| ACADIA PHARMACEUTICALS, INC. | 14 | Q1 2021 | 8.8% |
| ACCELERON PHARMA INC CMN | 14 | Q2 2020 | 8.2% |
| CONNECTURE INC | 13 | Q4 2017 | 25.1% |
View GREAT POINT PARTNERS LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| 89bio, Inc. | February 14, 2023 | 700,000 | 1.4% |
| KalVista Pharmaceuticals, Inc. | February 14, 2023 | 1,055,801 | 3.1% |
| Avalo Therapeutics, Inc. | February 13, 2023 | 974,639 | 7.1% |
| InflaRx N.V.Sold out | February 14, 2022 | 0 | 0.0% |
| ABEONA THERAPEUTICS INC.Sold out | February 16, 2021 | 0 | 0.0% |
| CONSTELLATION PHARMACEUTICALS INC | February 16, 2021 | 1,024,800 | 2.2% |
| GERON CORP | February 16, 2021 | 12,754,228 | 4.0% |
| Millendo Therapeutics, Inc. | February 16, 2021 | 270,000 | 1.4% |
| NextCure, Inc.Sold out | February 16, 2021 | 0 | 0.0% |
| PROTHENA CORP PUBLIC LTD CO | February 16, 2021 | 977,647 | 2.4% |
View GREAT POINT PARTNERS LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-04-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View GREAT POINT PARTNERS LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.